ENDOMYOCARDIAL MONOPHASIC ACTION POTENTIAL FOR EARLY DETECTION OF MYOCARDIUM PATHOLOGY

摘要

A 'lantern catheter' devised according to the invention is used for transpercutaneous catheterization followed by three-dimensionally mapping the endomyocardial monophasic action potential (MAP). Preferably at least 64 points of MAP are recorded simultaneously and the data analyzed by a conventional electrophysiological (EP) analysis system. The invention is comprised of three components: 1) the use of three-dimensional mapping of the endomyocardium (MAP) to determine the myocardium injury/electrical-pathophysiology of cardiac myocytes induced by cardiac rejection, ischemia, inflammation and the like; 2) a technology and design of the lantern catheter for endomyocardial MAP mapping; and 3) a diagnostic criteria for the cardiac myocyte injury. During allograft rejection, conduction impairment occurs only within the atrial myocardium.